Forbius
https://forbius.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Forbius
Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact
Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.
Medtech Deals In Depth: November 2021
Major medtech deals in November include Coloplast's $2.5bn acquisition of Atos Medical and Alcon's deal for Ivantis.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Sanofi Pastuer dengue vaccine enters Phase III
Sanofi Pasteur’s dengue vaccine candidate became the first of its type to enter phase III with announcement by the company of a new clinical study in Australia, part of global phase III clinical study programme for the prevention of dengue disease in children and adults.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Bristol Myers Squibb Company
- Formation Biologics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice